Yes, agree saftey and OBD are the main goal of the phase 1.
But like with most oncology phase 1 trials, the patient population aren't healthy volunteers, they're actual patients. Which means we also get to look for efficacy signals (responses).
Most of the oncology bios I follow don't get much of a SP kick from dose escalation/cohort safety announcements. What everyone is waiting for is more efficacy data, that's what excites the market and can set off a decent re-rate. Which is what we need to raise any meaningful cash.
Because CHM 1101 trial results are now at least a year away, we need either CDH17 or NK ADVENT (or both) to deliver some stellar interim results ASAP.
Otherwise well be giving away half the company to raise 2-3 quarters cash.
We really have got ourselves stuck in black hole. Let's hope the BoD can pull something out of the hat.
- Forums
- ASX - By Stock
- CHM
- Chimeric: Media Thread
Chimeric: Media Thread, page-819
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo
DVP
Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place
Add CHM (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.6¢ |
Change
-0.001(5.88%) |
Mkt cap ! $14.18M |
Open | High | Low | Value | Volume |
1.8¢ | 1.8¢ | 1.6¢ | $9.273K | 548.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 1365817 | 1.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.7¢ | 24633 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 1365817 | 0.016 |
8 | 658806 | 0.015 |
2 | 2300000 | 0.014 |
2 | 266900 | 0.013 |
3 | 916745 | 0.012 |
Price($) | Vol. | No. |
---|---|---|
0.017 | 24633 | 1 |
0.018 | 331802 | 4 |
0.019 | 330298 | 4 |
0.020 | 812725 | 6 |
0.021 | 420857 | 2 |
Last trade - 16.10pm 08/08/2024 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |